GLP1R and obesity due to melanocortin 4 receptor deficiency: Among incretins, GLP-1 (and specifically GLP-1 receptor agonists [GLP-1 RAs]) have gained the most popularity in treating T2D and obesity, with additional cardiovascular benefits (18, 341, 342).